Merge Healthcare’s advanced visualization software development subsidiary Cedara Software has released the I-Response application, a product designed to help evaluate, assess, and monitor the effect of cancer therapy over time using data from multiple modalities, according to the Toronto-based firm. The software provides tools for the standard anatomical measurements used for tumor assessment in cancer management and research, and can analyze both PET/CT and MR-based diffusion-weighted imaging (DWI), Cedara said.
The application provides the capability to visualize changes in tumors resulting from cellular and metabolic mechanisms during the course of treatment, Cedara said, and thus provide clinically relevant information that potentially could be used to make mid- treatment therapy adjustments in an attempt to improve clinical outcome.
I-Response also features proprietary functional Diffusion Map (fDM) technology based on research performed at the University of Michigan. The functionality enables physicians to analyze DWI studies to visualize and quantify changes over time in the microscopic motion of water in healthy and diseased tissues, the company said.
The results of each analysis are included in automatically generated reports, as well as exporting the results to file for import into a site's existing data repositories. I-Response is available to original equipment manufacturers (OEMs) as a standalone workstation. In addition, the company’s work-in-progress C4 integration platform will also allow the application to be integrated into existing PACS installations.